公开(公告)号：EP2603207A2

公开(公告)日：2013-06-19

申请号：EP11763981.5

申请日：2011-08-10

申请人： Lupin Limited

发明人： BHUTADA, Pravin, Meghrajji ,  DESHMUKH, Ashish, Ashokrao ,  CHANDRAN, Sajeev ,  KULKARNI, Shirishkumar

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K31/519 ,  A61K49/00 ,  A61K9/48

CPC分类号： A61K31/496 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/5026 ,  A61K9/5078 ,  A61K31/519

摘要： An oral controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) and optionally pharmaceutically acceptable excipients is provided. The present invention further relates to a controlled release pharmaceutical composition comprising Blonanserin and release controlling agent(s) such that the composition releases not less than about 80% of Blonanserin within 20 hours, when dissolution is carried out in 900 ml, 0.1 N HCI, USP apparatus Type II (Paddle) at 50 rpm for 20 hrs. The controlled release pharmaceutical composition of the invention releases 50% of Blonanserin between about 4 to 14 hours, when dissolution is carried out in 900 ml, 0.1 N HCI, USP apparatus Type II (Paddle) at 50 rpm.

公开(公告)号：EP2285353A1

公开(公告)日：2011-02-23

申请号：EP09706394.5

申请日：2009-01-30

申请人： Lupin Limited

发明人： KULKARNI, Sheetal ,  DAS, Srirupa ,  DESHMUKH, Ashish, Ashokrao ,  DALAL, Satish, Kumar ,  KULKARNI, Shirishkumar

IPC分类号： A61K9/20 ,  A61K31/22 ,  A61K31/505

CPC分类号： A61K9/2054 ,  A61K9/205 ,  A61K31/22 ,  A61K31/505

摘要： Modified release formulations of HMG Co-A reductase inhibitors, which provide reduced incidence of rhabdomyolysis, renal toxicity and other side effects by increasing hepatic bioavailability and decreasing systemic availability upon oral administration. The modified release pharmaceutical formulation comprises a therapeutically effective amount of HMG CoA reductase inhibitor or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), prodrug or metabolite thereof, one ore more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release formulation provides reduced incidence of adverse effects and improved efficacy when compared to the immediate release formulation upon oral administration.

公开(公告)号：EP2961393B1

公开(公告)日：2020-10-28

申请号：EP14710647.0

申请日：2014-02-27

申请人： Lupin Limited

发明人： BAKHLE, Dhananjay, Sadashiv ,  SHAH, Chirag, Anilkumar ,  GADVE, Snehal, Ameet ,  SHARMA, Neha ,  CHANDRAN, Sajeev ,  DESHMUKH, Ashish, Ashokrao

IPC分类号： A61K9/20 ,  A61K9/50 ,  A61K9/00 ,  A61K31/445 ,  A61P25/28 ,  A61K9/28 ,  A61P25/20 ,  A61P43/00

公开(公告)号：EP2391353B1

公开(公告)日：2016-02-10

申请号：EP09787579.3

申请日：2009-03-16

申请人： Lupin Limited

发明人： BHUTADA, Pravin, Meghrajji ,  DESHMUKH, Ashish, Ashokrao ,  DALAL, Satish , Kumar ,  KULKARNI, Shirishkumar

IPC分类号： A61K9/28 ,  A61K31/495

CPC分类号： A61K9/2866

公开(公告)号：EP2961392A1

公开(公告)日：2016-01-06

申请号：EP14710646.2

申请日：2014-02-27

申请人： Lupin Limited

发明人： BAKHLE, Dhananjay, Sadashiv ,  SHAH, Chirag, Anilkumar ,  GADVE, Snehal, Ameet ,  SHARMA, Neha ,  CHANDRAN, Sajeev ,  DESHMUKH, Ashish, Ashokrao

IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K9/24 ,  A61P25/28 ,  A61K31/445 ,  A61K9/22 ,  A61K9/00 ,  A61K9/50

摘要： A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a Paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° C., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.

摘要翻译： 多奈哌齐，包括定时释放的药物组合物被提供，worin所述组合物表现出的体外溶出曲线在37℃下在900毫升6.8的缓冲液以50rpm在桨式溶出仪测试时，小于约20％w / w的多奈哌齐的 被释放在3至6小时，而超过90％w / w的多奈哌齐的是12个小时后的释放。

公开(公告)号：EP2555756A2

公开(公告)日：2013-02-13

申请号：EP11711632.7

申请日：2011-02-07

申请人： Lupin Limited

发明人： DESHMUKH, Ashish, Ashokrao ,  BHUTADA, Pravin, Meghrajji ,  CHANDRAN, Sajeev ,  KULKARNI, Shirishkumar

IPC分类号： A61K9/20 ,  A61K9/16 ,  A61K9/50 ,  A61K45/06 ,  A61K31/137

CPC分类号： A61K9/209 ,  A61K9/0004 ,  A61K9/0065 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/137 ,  A61K45/06 ,  A61K2300/00

摘要： A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.

摘要翻译： 包含他喷他多的一次每日控释药物组合物，其中优选在施用组合物10小时后达到他喷他多的平均Tmax。 组合物包含他喷他多，使得其在口服给药组合物后至少约17小时维持至少约20ng / ml的他喷丹的血清浓度。 根据一个实施方案，控释药物组合物包含胃酸滞留的他喷他多。

公开(公告)号：EP2391353A1

公开(公告)日：2011-12-07

申请号：EP09787579.3

申请日：2009-03-16

申请人： Lupin Limited

发明人： BHUTADA, Pravin, Meghrajji ,  DESHMUKH, Ashish, Ashokrao ,  DALAL, Satish , Kumar ,  KULKARNI, Shirishkumar

IPC分类号： A61K9/28 ,  A61K31/495

CPC分类号： A61K9/2866

摘要： A once daily sustained release pharmaceutical compositions of Trimetazidine or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof using dual retard release technique. These compositions comprise a core comprising trimetazidine or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more sustained release polymer(s) in a matrix and one ore more pharmaceutically acceptable excipient(s), wherein the core is further coated with a functional coating. The compositions of the invention have reduced fluctuations of peak- valley plasma concentration as compared to 35mg twice daily modified release formulation.